bioRxivCancer BiologyPreprint
A multiprotein signaling complex sustains AKT and mTOR/S6K activity necessary for the survival of cancer cells undergoing stress
O. Y. Teran Pumar, M. R. Zanotelli, M.-c. J. Lin, R. R. Schmitt, K. S. Green, K. S. Rojas, I. Y. Hwang, R. A. Cerione, K. F. Wilson
Abstract
The ability of cancer cells to survive microenvironmental stresses is critical for tumor progression and metastasis; however, how they survive these challenges is not fully understood. Here, we describe a novel multiprotein complex (DockTOR) essential for the survival of cancer cells under stress, triggered by the GTPase Cdc42 and a signaling partner Dock7, which includes AKT, mTOR, and the mTOR regulators TSC1, TSC2, and Rheb. DockTOR enables cancer cells to maintain a low but critical mTORC2-dependent phosphorylation of AKT during serum deprivation by preventing AKT dephosphorylation through an interaction between phospho-AKT and the Dock7 DHR1 domain. This activity stimulates a Raptor-independent but Rapamycin-sensitive mTOR/S6K activity necessary for survival. These findings address long-standing questions of how Cdc42 signals result in mTOR activation and demonstrate how cancer cells survive conditions when growth factor-dependent activation of mTORC1 is off. Determining how cancer cells survive stress conditions could identify vulnerabilities that lead to new therapeutic strategies.
- research focus: cancer & tumor microenvironment
- research focus: cell signaling & trafficking
- research focus: cell type annotation
- approach: experimental assay
- approach: wet-lab / biochemical assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The mTORC1/S6K/PDCD4/eIF4A axis determines outcome of mitosis.
Mohamed Moustafa-Kamal, Thomas J. Kucharski, … Jose G. Teodoro·Cell ReportsPeer-reviewed·Oct 1, 2020
- Oncogenic Activation of AKT by MAPK6
- The Mixed Blessing of AMPK Signaling in Cancer Treatments
Mehrshad Sadria, Deokhwa Seo, Anita T. Layton·BMC CancerPeer-reviewed·Jan 25, 2022
- Simultaneous targeting of AMPK and mTOR is a novel therapeutic strategy against prostate cancer
G. Zhao, G. Forn-Cuni, … E. B. Snaar·bioRxiv·Aug 14, 2023
- Alkaline intracellular pH activates AMPK-mTORC2 signaling to promote cell survival during growth factor limitation
D. Kazyken, S. I. Lentz, D. C. Fingar·bioRxiv·May 13, 2021
- Dynamic Modeling of Signal Transduction by mTOR Complexes in Cancer
Mohammadreza Dorvash, Mohammad Farahmandnia, … Iman Tavassoly·Journal of Theoretical BiologyPeer-reviewed·Sep 4, 2019